TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
The latest update is out from MIRA Pharmaceuticals, Inc. ( (MIRA) ).
On September 22, 2025, MIRA Pharmaceuticals announced favorable topline results from the Phase 1 SAD study of their oral drug Ketamir-2, a next-generation non-scheduled ketamine analog. The study demonstrated that Ketamir-2 was safe and well tolerated at all dose levels, with no severe adverse effects, and showed a predictable pharmacokinetic profile supporting once-daily dosing. The company plans to initiate the multiple ascending dose portion of the Phase 1 study, followed by a Phase 2a trial in patients with neuropathic pain, indicating a positive step forward in their drug development process.
The most recent analyst rating on (MIRA) stock is a Buy with a $17.00 price target. To see the full list of analyst forecasts on MIRA Pharmaceuticals, Inc. stock, see the MIRA Stock Forecast page.
More about MIRA Pharmaceuticals, Inc.
MIRA Pharmaceuticals, Inc. operates in the pharmaceutical industry, focusing on developing next-generation non-scheduled ketamine analogs, with a market focus on treatments for conditions such as neuropathic pain.
Average Trading Volume: 1,517,010
Technical Sentiment Signal: Sell
See more data about MIRA stock on TipRanks’ Stock Analysis page.